Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 217

1.

Metabolic imaging metrics correlate with survival in early stage lung cancer treated with stereotactic ablative radiotherapy.

Abelson JA, Murphy JD, Trakul N, Bazan JG, Maxim PG, Graves EE, Quon A, Le QT, Diehn M, Loo BW Jr.

Lung Cancer. 2012 Dec;78(3):219-24. doi: 10.1016/j.lungcan.2012.08.016. Epub 2012 Sep 23.

PMID:
23009727
2.

Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.

Zhang H, Wroblewski K, Liao S, Kampalath R, Penney BC, Zhang Y, Pu Y.

Acad Radiol. 2013 Jan;20(1):32-40. doi: 10.1016/j.acra.2012.07.002. Epub 2012 Sep 19.

PMID:
22999369
3.

Residual ¹⁸F-FDG-PET uptake 12 weeks after stereotactic ablative radiotherapy for stage I non-small-cell lung cancer predicts local control.

Bollineni VR, Widder J, Pruim J, Langendijk JA, Wiegman EM.

Int J Radiat Oncol Biol Phys. 2012 Jul 15;83(4):e551-5. doi: 10.1016/j.ijrobp.2012.01.012. Epub 2012 Mar 13.

PMID:
22417800
4.

Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer.

Liao S, Penney BC, Wroblewski K, Zhang H, Simon CA, Kampalath R, Shih MC, Shimada N, Chen S, Salgia R, Appelbaum DE, Suzuki K, Chen CT, Pu Y.

Eur J Nucl Med Mol Imaging. 2012 Jan;39(1):27-38. doi: 10.1007/s00259-011-1934-6. Epub 2011 Sep 23.

PMID:
21946983
5.
6.

Volume-based parameters measured by using FDG PET/CT in patients with stage I NSCLC treated with stereotactic body radiation therapy: prognostic value.

Satoh Y, Onishi H, Nambu A, Araki T.

Radiology. 2014 Jan;270(1):275-81. doi: 10.1148/radiol.13130652. Epub 2013 Oct 28.

PMID:
24029640
7.

Maximum standardized uptake value from staging FDG-PET/CT does not predict treatment outcome for early-stage non-small-cell lung cancer treated with stereotactic body radiotherapy.

Burdick MJ, Stephans KL, Reddy CA, Djemil T, Srinivas SM, Videtic GM.

Int J Radiat Oncol Biol Phys. 2010 Nov 15;78(4):1033-9. doi: 10.1016/j.ijrobp.2009.09.081. Epub 2010 May 14.

PMID:
20472359
8.

Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer.

Chen HH, Chiu NT, Su WC, Guo HR, Lee BF.

Radiology. 2012 Aug;264(2):559-66. doi: 10.1148/radiol.12111148. Epub 2012 Jun 12.

PMID:
22692034
9.

Pretreatment SUVmax predicts progression-free survival in early-stage non-small cell lung cancer treated with stereotactic body radiation therapy.

Horne ZD, Clump DA, Vargo JA, Shah S, Beriwal S, Burton SA, Quinn AE, Schuchert MJ, Landreneau RJ, Christie NA, Luketich JD, Heron DE.

Radiat Oncol. 2014 Jan 30;9:41. doi: 10.1186/1748-717X-9-41.

10.

7-year follow-up after stereotactic ablative radiotherapy for patients with stage I non-small cell lung cancer: Results of a phase 2 clinical trial.

Sun B, Brooks ED, Komaki RU, Liao Z, Jeter MD, McAleer MF, Allen PK, Balter PA, Welsh JD, O'Reilly MS, Gomez D, Hahn SM, Roth JA, Mehran RJ, Heymach JV, Chang JY.

Cancer. 2017 Aug 15;123(16):3031-3039. doi: 10.1002/cncr.30693. Epub 2017 Mar 27.

PMID:
28346656
11.

Oncologic outcomes of segmentectomy compared with lobectomy for clinical stage IA lung adenocarcinoma: propensity score-matched analysis in a multicenter study.

Tsutani Y, Miyata Y, Nakayama H, Okumura S, Adachi S, Yoshimura M, Okada M.

J Thorac Cardiovasc Surg. 2013 Aug;146(2):358-64. doi: 10.1016/j.jtcvs.2013.02.008. Epub 2013 Mar 8.

12.

Postchemoradiotherapy positron emission tomography predicts pathologic response and survival in patients with esophageal cancer.

Jayachandran P, Pai RK, Quon A, Graves E, Krakow TE, La T, Loo BW Jr, Koong AC, Chang DT.

Int J Radiat Oncol Biol Phys. 2012 Oct 1;84(2):471-7. doi: 10.1016/j.ijrobp.2011.12.029. Epub 2012 Feb 28.

PMID:
22381904
13.

Textural features in pre-treatment [F18]-FDG-PET/CT are correlated with risk of local recurrence and disease-specific survival in early stage NSCLC patients receiving primary stereotactic radiation therapy.

Pyka T, Bundschuh RA, Andratschke N, Mayer B, Specht HM, Papp L, Zsótér N, Essler M.

Radiat Oncol. 2015 Apr 22;10:100. doi: 10.1186/s13014-015-0407-7.

14.

18F-FDG PET and combined 18F-FDG-contrast CT parameters as predictors of tumor control for hepatocellular carcinoma after stereotactic ablative radiotherapy.

Huang WY, Kao CH, Huang WS, Chen CM, Chang LP, Lee MS, Chao HL, Chiu CH, Lo CH, Jen YM.

J Nucl Med. 2013 Oct;54(10):1710-6. doi: 10.2967/jnumed.112.119370. Epub 2013 Aug 22.

15.

Prognostic value of volumetric parameters measured by F-18 FDG PET/CT in surgically resected non-small-cell lung cancer.

Kim K, Kim SJ, Kim IJ, Kim YS, Pak K, Kim H.

Nucl Med Commun. 2012 Jun;33(6):613-20. doi: 10.1097/MNM.0b013e328351d4f5.

PMID:
22407127
16.

Prognostic significance of metabolic parameters measured by (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with small cell lung cancer.

Zhu D, Ma T, Niu Z, Zheng J, Han A, Zhao S, Yu J.

Lung Cancer. 2011 Sep;73(3):332-7. doi: 10.1016/j.lungcan.2011.01.007. Epub 2011 Feb 2.

PMID:
21292341
17.

Revisiting the prognostic value of preoperative (18)F-fluoro-2-deoxyglucose ( (18)F-FDG) positron emission tomography (PET) in early-stage (I & II) non-small cell lung cancers (NSCLC).

Agarwal M, Brahmanday G, Bajaj SK, Ravikrishnan KP, Wong CY.

Eur J Nucl Med Mol Imaging. 2010 Apr;37(4):691-8. doi: 10.1007/s00259-009-1291-x. Epub 2009 Nov 14.

18.
19.

Volume-based parameters of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography improve outcome prediction in early-stage non-small cell lung cancer after surgical resection.

Hyun SH, Choi JY, Kim K, Kim J, Shim YM, Um SW, Kim H, Lee KH, Kim BT.

Ann Surg. 2013 Feb;257(2):364-70. doi: 10.1097/SLA.0b013e318262a6ec.

PMID:
22968069
20.

Prognostic value of metabolic tumor volume and total lesion glycolysis from ¹⁸F-FDG PET/CT in patients undergoing stereotactic body radiation therapy for stage I non-small-cell lung cancer.

Vu CC, Matthews R, Kim B, Franceschi D, Bilfinger TV, Moore WH.

Nucl Med Commun. 2013 Oct;34(10):959-63. doi: 10.1097/MNM.0b013e32836491a9.

PMID:
23921784

Supplemental Content

Support Center